{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bakai TA"],"funding":["Association Nationale de la Recherche et de la Technologie","Région Auvergne-Rhône-Alpes","Association Nationale de la Recherche et de la Technologie (ANRT)","EPIMOD"],"pagination":["400"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9804945"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>In 2012, the World Health Organization (WHO) recommended seasonal malaria chemoprevention (SMC) in areas of high seasonal transmission. Though implemented since 2013, the effectiveness of SMC in Togo was never evaluated.<h4>Methods</h4>This study concerned routine data from 2013 to 2020 mass SMC campaigns for children under five in all health facilities of three Regions of Togo. Treatment coverage, reasons for non-treatment, and SMC-attributable adverse reactions were analysed per year and treatment round. Random effect logistic models estimated SMC effectiveness per health district, year, and treatment round.<h4>Results</h4>The overall coverage was 98% (7,971,877 doses for 8,129,668 children). Contraindication was the main reason for non-administration. Over the study p"],"journal":["Malaria journal"],"pubmed_title":["Effectiveness of seasonal malaria chemoprevention in three regions of Togo: a population-based longitudinal study from 2013 to 2020."],"pmcid":["PMC9804945"],"funding_grant_id":["Grant 19 003 721 01","CIFRE 2017/1805"],"pubmed_authors":["Thomas A","Rabilloud M","Atcha-Oubou T","Voirin N","Tchadjobo T","Khanafer N","Iwaz J","Bakai TA"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of seasonal malaria chemoprevention in three regions of Togo: a population-based longitudinal study from 2013 to 2020.","description":"<h4>Background</h4>In 2012, the World Health Organization (WHO) recommended seasonal malaria chemoprevention (SMC) in areas of high seasonal transmission. Though implemented since 2013, the effectiveness of SMC in Togo was never evaluated.<h4>Methods</h4>This study concerned routine data from 2013 to 2020 mass SMC campaigns for children under five in all health facilities of three Regions of Togo. Treatment coverage, reasons for non-treatment, and SMC-attributable adverse reactions were analysed per year and treatment round. Random effect logistic models estimated SMC effectiveness per health district, year, and treatment round.<h4>Results</h4>The overall coverage was 98% (7,971,877 doses for 8,129,668 children). Contraindication was the main reason for non-administration. Over the study p","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-05-29T16:22:40.83Z","creation":"2025-05-29T16:22:40.83Z"},"accession":"S-EPMC9804945","cross_references":{"pubmed":["36587191"],"doi":["10.1186/s12936-022-04434-w"]}}